InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
8
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Namouni Fouad, Président et Directeur de la Recherche et Développement. Insider active across 2 companies, notably Aprea Therapeutics, Inc.. In total, 14 reports have been published. Breakdown: 0 buy · 8 sells. Total volume traded: €2m. Activity tracked since 30 June 2021. The latest transaction was disclosed on 5 March 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Namouni Fouad
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
39,456 sharesCommon StockSEC:0001104659-25-069383:0
6,489 shares@ US$88.8023.7% of flowCommon StockSEC:0001415889-25-007402:0
13,200 shares0Common StockSEC:0001415889-25-006602:0
3,633 shares@ US$89.3212.8% of flowCommon StockSEC:0001415889-24-024776:0
4,377 shares@ US$90.6915.9% of flowCommon StockSEC:0001415889-24-007554:0
15,000 shares0Common StockSEC:0001415889-24-007021:0
3,769 shares@ US$48.067.5% of flowCommon StockSEC:0001415889-23-014022:0
1,885 shares@ US$45.723.5% of flowCommon StockSEC:0001415889-23-004564:0
15,000 shares0Common StockSEC:0001415889-23-004262:0
3,477 shares@ US$67.3010.2% of flowCommon StockSEC:0001415889-22-010366:0
1,047 shares@ US$56.192.7% of flowCommon StockSEC:0001415889-22-002738:0
15,000 shares0Common StockSEC:0001415889-22-002432:0
3,241 shares@ US$98.1813.6% of flowCommon StockSEC:0001179110-21-009297:0
4,610 shares0Common StockSEC:0001567619-21-012871:0
14 of 14 declarations
About Namouni Fouad
Namouni Fouad is President and Head of Research and Development. He is associated with Blueprint Medicines Corp and Aprea Therapeutics, Inc., and his 14 filings, based on the recent sample of 14 filings, cover disposals between 2021-07-01 and 2025-07-21 for a total of EUR 2016838.
